



SCOHIA PHARMA, Inc.

August 11, 2020

**SCOHIA initiates a phase 1 study on
a dual GLP-1 and GIP receptor agonist (SCO-094)**

SCOHIA PHARMA, Inc., announced today that a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic peptide (GIP) receptor agonist (SCO-094) has progressed to a phase 1 study in type 2 diabetes mellitus patients.

This is a randomized, placebo-controlled, double-blind, single-center study conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of SCO-094 in patients with type 2 diabetes mellitus in the United Kingdom.

For more information about the study, please visit the following website:

<https://www.clinicaltrials.jp/cti-user/trial/Search.jsp>

(Please search using JapicCTI-205323).

[About dual GLP-1 and GIP receptor agonist (SCO-094)]

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic peptide (GIP) are gut hormones called incretins. They physiologically regulate metabolism and body weight via their receptors (GLP-1R and GIPR). Recent advances in the combination of GIPR agonism with GLP-1R agonism have shown superior efficacy to GLP-1R agonism only. SCO-094, identified by SCOHIA researchers and collaborators, is a novel dual agonist for GLP-1R and GIPR. Preclinical studies have shown that SCO-094 is more effective in improving diabetes and obesity than GLP-1R agonism only. In addition, SCO-094 has been shown to improve liver parameters in diabetic and obesity conditions in preclinical research. For detailed information about SCO-094, please visit <https://www.scohia.com/eng/sys/pipeline/sco-094/>

[About SCOHIA PHARMA, Inc.]

SCOHIA PHARMA, Inc. is a drug discovery bioventure focusing on the field of lifestyle-related diseases such as cardiovascular, metabolic, and renal diseases. Our R&D team has a rich pipeline and track record in each stage of drug development, including compound discovery, drug evaluation, and clinical development, which



makes us special. For detailed information about SCOHIA PHARMA, Inc., please visit <https://www.scohia.com/eng/>.

Contact for inquiries: info@scohia.com